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Abstract
Background: Deficiencies in effective flukicide options and growing issues with drug resistance make current
strategies for liver fluke control unsustainable, thereby promoting the need to identify and validate new control
targets in Fasciola spp. parasites. Calmodulins (CaMs) are small calcium-sensing proteins with ubiquitous expression
in all eukaryotic organisms and generally use fluctuations in intracellular calcium levels to modulate cell signalling
events. CaMs are essential for fundamental processes including the phosphorylation of protein kinases, gene
transcription, calcium transport and smooth muscle contraction. In the blood fluke Schistosoma mansoni,
calmodulins have been implicated in egg hatching, miracidial transformation and larval development. Previously,
CaMs have been identified amongst liver fluke excretory-secretory products and three CaM-like proteins have been
characterised biochemically from adult Fasciola hepatica, although their functions remain unknown.
Methods: In this study, we set out to investigate the biological function and control target potential of F. hepatica
CaMs (FhCaMs) using RNAi methodology alongside novel in vitro bioassays.
Results: Our results reveal that: (i) FhCaMs are widely expressed in parenchymal cells throughout the forebody
region of juvenile fluke; (ii) significant transcriptional knockdown of FhCaM1-3 was inducible by exposure to either
long (~200 nt) double stranded (ds) RNAs or 27 nt short interfering (si) RNAs, although siRNAs were less effective
than long dsRNAs; (iii) transient long dsRNA exposure-induced RNA interference (RNAi) of FhCaMs triggered
transcript knockdown that persisted for ≥ 21 days, and led to detectable suppression of FhCaM proteins; (iv) FhCaM
RNAi significantly reduced the growth of juvenile flukes maintained in vitro; (v) FhCaM RNAi juveniles also displayed
hyperactivity encompassing significantly increased migration; (vi) both the reduced growth and increased motility
phenotypes were recapitulated in juvenile fluke using the CaM inhibitor trifluoperazine hydrochloride, supporting
phenotype specificity.
Conclusions: These data indicate that the Ca2+-modulating functions of FhCaMs are important for juvenile fluke
growth and movement and provide the first functional genomics-based example of a growth-defect resulting from
gene silencing in liver fluke. Whilst the phenotypic impacts of FhCaM silencing on fluke behaviour do not strongly
support their candidature as new flukicide targets, the growth impacts encourage further consideration, especially
in light of the speed of juvenile fluke growth in vivo.
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Background
Fasciola spp. liver flukes cause fasciolosis, a disease that
impacts heavily on farmed animal health and food secur-
ity, and is of growing importance as a human neglected
tropical disease [1–3]. There are only a handful of avail-
able flukicides with which to combat these infections,
and their utility is being eroded by the increasing occur-
rence of drug resistance in both veterinary and human
infections [4, 5]. Triclabendazole is the only flukicide
with significant activity against juvenile liver fluke [6],
the life-cycle stage that causes host tissue damage during
its migration from the gut lumen, through the intestinal
mucosa and hepatic parenchyma to the bile ducts. Novel
flukicides, especially those with activity against juvenile
fluke, are a pressing need.
Calcium ions (Ca2+) are ubiquitous messengers with
an array of roles in physiological and metabolic path-
ways. External stimuli or signals often lead to variations
in intracellular Ca2+ levels that regulate processes such
as transcription, neurotransmitter release and muscle
function [7]. The range of responses that can result from
Ca2+ signalling are a direct result of the temporal and
spatial organisation of the signal [8]. In many cases, par-
ticularly longer acting responses, effector proteins can-
not bind Ca2+ directly and require an intermediate Ca2+
sensing protein in order to initiate a biological response.
Calmodulin (CaM) is the most studied Ca2+ sensing
protein in mammals and can act as a monomer, or as a
subunit in multimeric proteins [9]. Within its dumbbell
shape it possesses two globular domains, each with the
ability to bind two Ca2+ ions (four binding sites per
CaM), connected by a flexible linker region. Normally,
cytosolic Ca2+ levels are low, but even a small rise in
cytosolic [Ca2+] can trigger Ca2+ binding and a conform-
ational change in CaM that facilitates the interaction be-
tween the Ca2+/CaM complex and target proteins [10].
The cooperative binding properties of CaM mean that
small increases in cytosolic Ca2+ can be translated, via
CaM and other calcium sensors, to a multitude of bio-
logical processes such as transcription, muscle activity,
neurotransmission, cytoskeletal assembly/reorganisation
and cell death [10, 11]. The key role played by CaM in
diverse biological processes makes it an appealing target
for the control of pathogens. Indeed, the disruption of
Ca2+ regulation is believed to be key to the mode of ac-
tion of praziquantel, used for the control of Schistosoma
mansoni and various cestodiases [12].
Despite this interest, CaMs in flatworms are still quite
poorly understood. CaM-like proteins have been identi-
fied in several important fluke species. Two CaMs have
been identified and characterised from S. mansoni [13],
showing high sequence identity (>98 %) to CaMs from
mammals. Silencing these schistosome CaMs using RNA
interference (RNAi) resulted in shorter worms in larval
stages and somatic muscle contraction/dilation in adults,
while CaM antagonists inhibited miracidial transform-
ation in a concentration dependent manner [13, 14].
Previously, a CaM inhibitor was shown to inhibit egg
hatching and miracidial transformation in S. mansoni
[15, 16]. A Clonorchis sinensis CaM was shown to bind
Ca2+ and to be expressed in diverse developmental
stages including the egg, metacercaria and adult where it
was localised in the intestine, pharynx and tegument
[17]. A divergent CaM-like protein has been reported in
Schistosoma japonicum [18] and three CaM-like proteins
have been identified and biochemically described in Fas-
ciola hepatica [19, 20]. The first, FhCaM1, displays high
identity to mammalian CaM with only two amino acids
differing. FhCaM2 and FhCaM3 are more divergent, dis-
playing lower sequence similarity, as well as distinct bio-
chemical and ion binding properties. This prompted the
hypothesis that they are involved in different pathways
or perform roles distinct from that of FhCaM1 in the or-
ganism. All three fluke CaMs were predicted to adopt a
calmodulin-like fold and shown to bind Ca2+. Immuno-
cytochemistry failed to detect FhCaM1 but localised
FhCaM2 and FhCaM3 to eggs and vitelline cells in adult
worms [19, 20].
This study builds upon our description of RNAi dy-
namics in juvenile fluke [21], employing RNAi methods
to investigate the biological functions of FhCaM1,
FhCaM2 and FhCaM3 in juvenile F. hepatica. We show
that FhCaM2 and FhCaM3 are expressed widely in par-
enchymal cells of juvenile fluke and that FhCaM RNAi
inhibits growth and modulates motility, phenotypes that
can be recapitulated using a CaM antagonist drug. These
data provide the first functional data for liver fluke cal-
modulins, including the first description of an RNAi-
induced growth phenotype in liver fluke, suggesting that
drugs capable of targeting CaM’s role in growth/develop-
ment might represent appealing new additions to our
flukicidal arsenal.
Methods
Parasites and maintenance
F. hepatica metacercariae (Oregon strain) were pur-
chased from Baldwin Aquatics Inc. (Monmouth, Or,
USA) and stored in distilled water at 4 °C. These meta-
cercariae were supplied without their outer cyst walls,
with excystment performed as described previously [22].
Worms were transferred, as they excysted, into RPMI
1640 supplemented with antibiotic/antimycotic (100 U/
ml penicillin, 100 μg/ml streptomycin and 25 μg/ml
amphotericin B, Life Technologies, Carlsbad, USA), be-
fore further processing as described below. At all stages
of these experiments, excysted juvenile fluke were han-
dled under aseptic conditions and maintained at 37 °C
in a humidified 5 % CO2 atmosphere.
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Genomic organisation of CaM encoding genes
The F. hepatica genome [23] was queried using
tBLASTn analysis for the translated sequences of
FhCaM1, FhCaM2, and FhCaM3. Returned hits were
assessed for bit score and E-value and manually assem-
bled from the parent scaffold using Artemis to decipher
exon organisation [24]. Contigs were aligned pairwise
with the corresponding query sequence to ensure
identity.
Immunocytochemistry
Freshly excysted fluke were fixed for 4 h at room
temperature in 4 % paraformaldehyde in 0.1 M Phos-
phate Buffered Saline (PBS prepared from tablets; Sigma
Aldrich, St Louis, USA). Primary antisera were raised in
rabbits against each of the following: recombinant
human-CaM (structurally similar to FhCaM1 and differs
by two amino acids; antiserum shown previously to
cross-react with FhCaM1; Sigma-Aldrich); FhCaM2;
and, FhCaM3 [19, 20]. Incubations in primary antisera
were performed at 1/200 dilution (diluted in antibody di-
luent, AbD; 0.1 M PBS, 0.1 % (v/v) TritonX-100, 0.1 %
(w/v) bovine serum albumin, 0.1 % (w/v) NaN3) for two
days. Samples were then incubated consecutively in
secondary antibody (fluorescein isothiocyanate (FITC)-
labelled goat anti-rabbit; 1:100) overnight, and then
overnight in tetramethylrhodamine isothiocyanate
(TRITC)-labelled phalloidin (200 ng/ml), both diluted in
AbD. Incubations were performed at 4 °C unless stated
otherwise, and at least three washes in 1 M NaCl in
PBS, 0.1 % TritonX-100, 0.2 % Tween-20, were per-
formed between incubations. Samples were mounted in
Vectashield (Vector Laboratories, Peterborough, UK)
and viewed on a Leica TCS SP5 confocal scanning laser
microscope.
CaM RNAi methodology
CaM transcript dsRNA templates were amplified from
PCR amplicons representing the coding sequence of
each CaM gene. These coding sequences were amplified
using the following primers, designed against the Gen-
Bank accession numbers provided: FhCaM1 [AM412546],
forward 5’-atggctgatcaactcacagaaga-3’, reverse 5’-tcattttg-
cagtcatcattttcac-3’; FhCaM2 [AM412547], forward 5’-
ggtgcaccatctctcacaag-3’, reverse 5’-ttgcgcagaagagtcaagaa-3’;
FhCaM3 [JQ792169], forward 5’-atggctgactttgatatggatca-
3’, reverse 5’-ctacaggtattcgtatgcaaattcc-3’. Templates for
dsRNA constructs were amplified from these primary
amplicons in a nested PCR reaction, using primers la-
belled (on 5’ end) with a T7 RNA polymerase promoter
sequence (5’-taatacgactcactatagggt-3’), to create templates
labelled with T7 in either sense or antisense directions
(FhCaM1, forward 5’- cagaagagcagatcgcagaa-3’, reverse
5’-aattcggggaaatcaatggt-3’; FhCaM2, forward 5’-
agatgccacggaactgaaag-3’, reverse 5’-aaatgtacccgtcgccatta-3’;
FhCaM3, forward 5’- atgacgctgtacgacaccaa-3’, reverse 5’-
agtggtgggcacaacgatac-3’). All PCR amplicons were se-
quence confirmed [25]. This approach generated dsRNA
templates for FhCaM1, 2, and 3 of 190 bp, 221 bp and
210 bp, respectively. Exogenously derived (i.e. non-worm)
negative control dsRNA templates (bacterial neomycin
phosphotransferase; [U55762]) were generated from the
cloning vector pEGFP-NI (Clontech Laboratories Inc.,
Saint-Germain-en-Laye, France), using the following
primers: forward, 5’-ggtggagaggctattcggct-3’; reverse: 5’-
ccttcccggttcagtgacaa-3’. These templates were used to
generate double stranded (ds)RNAs as described in
McVeigh et al. [21].
Short interfering (si)RNAs (27mer) for each FhCaM
were designed and synthesised by [26]; a randomised
siRNA control was also used. Target sequences for these
siRNAs were as follows: FhCaM1, 5’-augacugucccaagcuc-
cuucguggua-3’; FhCaM2, 5’-uauguaagacugaucucaauu-
cuuccg-3’; FhCaM3, 5'-ucccugucacuaacccuccucuuuguu-3’;
and negative control siRNA sequence siCTRL, 5’-
cttcctctctttctctcccttgtga-3’.
In order to expose juvenile fluke to RNAi trigger mol-
ecules, fluke were soaked (20 NEJs per replicate for tran-
scriptional analysis, 10 NEJs per replicate for phenotype
assays and 50 NEJs per replicate for western blot ana-
lysis) in 50 μl of 100 ng/μl (dsRNA), or 50 ng/μl (siRNA)
solution of FhCaM ds/siRNA dissolved in RPMI 1640,
alongside both untreated (no ds/siRNA) and negative
control (dsCTRL/siCTRL) treatments, with all soaks
performed at least in triplicate. Soaks were performed
for 4 h at 37 °C, in 5 % CO2. After this 4 h incubation,
250 μl maintenance media was added (RPMI 1640, con-
taining antibiotic/antimycotic and supplemented with
20 % foetal bovine serum (FBS)). Worms were main-
tained in this medium for up to 21 days with a change
of media once every 2–3 days. During media changes
worms were observed using light microscopy for obvious
phenotypic changes (aberrant morphology or motility),
or imaged for measurements as described below.
Transcript quantification
Transcript abundance was assessed in NEJs maintained
in the presence (+) and absence (−) of serum in the
maintenance media at 0-, 1-, 3-, 5- and 7-days. Note that
97 % of juvenile fluke are viable by day 7 in RPMI and
100 % are viable in RPMI supplemented with serum.
Parasites remain viable and motile for several weeks
under these conditions (data not shown). For RNAi
experiments, transcript abundance was assessed follow-
ing maintenance at 3-, 14- and 21-days post dsRNA (or
siRNA) exposure, by quantitative PCR (qPCR). Poly-
adenylated mRNA, extracted from treatment groups (20
NEJs per replicate) using Dynabeads mRNA direct Kit
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(Life Technologies, Carlsbad, USA), was used to synthe-
sise cDNA (High Capacity RNA-to-cDNA kit, Life Tech-
nologies) following DNase treatment (Turbo DNA-free,
Life Technologies). qPCRs were performed on a Rotor-
Gene Q 5-plex HRM PCR system (Qiagen), using the
following gene-specific primers: FhCaM1, forward 5’-
tggtaacgggaccattgatt-3’, reverse 5’- ttatcgaacacacggaatgc-
3’; FhCaM2, forward 5’- atcgcggcaatcttgataat-3’, reverse
5’-ttgcgcagaagagtcaagaa-3’; FhCaM3, forward 5’-
agcttcggaactgcacaaat-3’, reverse 5’-cgttgtcaccatctttgtcg-3’.
Target primers were amplified alongside the glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) reference
transcript (FhGAPDH [GenBank; AY005475]), forward
5’-ggctgtgggcaaagtcattc-3’, reverse 5’-
agatccacgacggaaacatca-3’). Primers were added to 8 μl
PCR reactions at a final concentration of 1.25 μM, in-
cluding cDNA diluted 1:1 with water, and FastStart
SYBR Green Master (Roche Applied Science). Cycling
parameters employed were a 10 min “hot-start” at 95 °C,
followed by 40 cycles of 95 °C 10 s, 60 °C 15 s, 72 °C
30 s. All PCRs were performed in triplicate, and in-
cluded no-template controls and melt-curve analyses as
standard. Relative expression analysis employed Pfaffl’s
Augmented ΔΔCt method [27] (which normalises ex-
pression in each sample relative to the untreated control,
standardised to a GAPDH reference amplicon), with
amplification efficiencies of individual reactions calcu-
lated using Real Time PCR Miner software [28, 29]. This
analysis method produces a ratio of target transcript
abundance relative to the untreated control, which was
then converted into percentage change (i.e. where a
value of 100 % represents no change). These data (mean
% transcript abundance relative to FhGAPDH reference
± SEM) are plotted in bar graphs in the qPCR figures.
All datasets were normally distributed according to the
Kolmogorov-Smirnov test and were, therefore, analysed
using ANOVA with Tukey's or Dunnett’s multiple com-
parison post hoc test. Statistical significance was
determined relative to the effects of negative control
treatments (dsCTRL or siCTRL) on target gene
expression.
Analysis of CaM protein
Protein abundance was assessed after RNAi treatments
and maintenance in the presence of serum at days −7 and
−14 post dsRNA, using western blot methods. Protein was
extracted from tissue matched (50 NEJs) homogenised
treatment groups in 50 μl radioimmunoprecipitation assay
(RIPA) buffer (Sigma-Aldrich), with blots performed as
described previously [30]. Following protein transfer onto
nitrocellulose membrane, the top half of each membrane
(relatively high molecular weight proteins) was probed
with rabbit anti-actin (1:400) (Sigma Aldrich) as a loading
control. The bottom half (relatively low molecular weight
proteins) was probed with rabbit anti-HsCaM1 (1:1000),
rabbit anti-FhCaM2 (1:1000) or rabbit anti-FhCaM3
(1:1000); these incubations were performed in parallel.
Secondary antibody was an alkaline phosphatase conju-
gated goat-anti-rabbit (Sigma Aldrich), used at 1:1000 di-
lution. Development was performed in nitro blue
tetrazolium chloride/5-bromo-4-chloro-3-indolyl-phos-
phate, toluidine-salt (NBT/BCIP) solution.
CaM antagonists
We used the CaM antagonists, trifluoperazine hydro-
chloride (TFP) and N-(6-aminohexyl)-5-chloro-1-
naphthalenesulfonamide hydrochloride (W7) (both
Sigma Aldrich) [31]. Drugs were dissolved in 100 %
dimethylsulfoxide (DMSO) and added to maintenance
media such that the final DMSO concentration was
0.1 %. Two methods of administration were employed:
(i) short term exposure performed in RPMI 1640 for
18 h at final concentrations 10, 5, 2 and 0.5 μM, includ-
ing vector (DMSO) only control and untreated control;
and (ii) long term exposure performed in RPMI + 20 %
FBS over 7 days in constant presence of TFP with final
concentrations at 5, 1, 0.5, 0.1, 0.05 μM plus controls as
outlined above.
Phenotypic analyses
Following RNAi and drug treatments, we assayed for
changes in both motility/migration and growth pheno-
types. All analyses were performed in an operator-
blinded fashion, on coded samples. Analysis of worm
motility was performed on drug-treated (18 h) worms by
capturing videos (30 s), and manually counting the num-
bers of worms displaying full, “normal” motility (i.e.
waves of circular muscle contraction travelling from an-
terior to posterior) during the analysis period. Analysis
of migration was performed on both drug treated and
RNAi-treated worms. Migratory capacity under these ex-
perimental conditions was assessed using an agar disper-
sal assay, in which worms were placed into an agar
substrate (0.2 % cell culture grade agar (Sigma Aldrich)
in HEPES-buffered Ringer’s (123 mM NaCl, 5 mM KCl,
1.6 mM CaCl2, 20 mM HEPES, 11.1 mM d-glucose;
pH 7.4)) at the centre of a petri dish. The proportion of
worms migrating beyond an empirically determined ra-
dius (5 mm) was then recorded over a 3 h time-course
using a measuring grid under a dissecting microscope.
Growth analyses were performed on both drug and
RNAi treated worms (and controls). Images captured
using a Leica MZ 12.5 stereomicroscope and Unibrain
Fire-i digital camera were subject to measurements of
length and area using the measurement tools in ImageJ
software [32]. Growth and motility assay data were ana-
lysed using one-way ANOVA with Dunnett’s post hoc
test, analysing significance of treatments relative to the
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negative control ds/siRNA treated worms (RNAi experi-
ments), or vehicle control treated worms (drug
experiments).
Results and Discussion
This study reports functional characterisation of three
CaM-like proteins in F. hepatica juveniles. Although the
in vitro biochemistry of the three FhCaM recombinants,
and their adult localisations have been reported previ-
ously [19, 20], functional genomics analyses have not
been performed on CaMs in any F. hepatica life-cycle
stage. Motivated by reports of CaM RNAi phenotypes in
other helminths [13, 33] we focused here on assessing
CaM function in juvenile fluke, given the amenability of
this life-cycle stage to our target validation platform for
fluke that encompasses RNAi methods [21, 22, 34] and
diverse functional assay platforms. A primary motivation
for focusing on CaM, a protein intimately involved in
cellular Ca2+ signalling processes, is the fact that Ca2+
signalling and regulation play key roles in neuromuscu-
lar function, which represents a well-established reposi-
tory of targets for empirically-discovered anthelmintics
[35]. Indeed, the disruption of Ca2+ regulation by prazi-
quantel, the drug of choice for the treatment of schisto-
some and tapeworm infections, directly highlights the
validity of interventions disrupting Ca2+ signalling/regu-
lation. Whilst previous work on liver fluke CaMs fo-
cussed on in vitro function and adult stage expression,
our focus was CaM expression and biological import-
ance as a measure of control target validity in juvenile
fluke. It is well established that effective flukicides need
to target both the migrating juvenile and adult fluke
stages. In this way our data inform CaM expression,
function, and potential as a therapeutic target for liver
fluke control.
Genomic organisation
Analysis of hits collected from querying the genomic
dataset with pre-confirmed FhCaM1, FhCaM2 and
FhCaM3 protein sequences revealed that the FhCaM1
gene exists in at least two intronless copies on scaffold
932: one full length with an S18F substitution, and one
missing the initial 18 amino acids due to an undefined
region on the scaffold (Additional file 1: Figure S1). A
third copy of FhCaM1 is present on scaffold 210 (exists
as 4 exons) with a stop codon (TAG) in place of the ini-
tiating methionine. This could represent a sequencing
error or the premature stop codon may indicate that the
third FhCaM1 copy is a pseudogene that would not be
translated but could play alternative regulatory roles.
FhCaM2 is present as a single copy on scaffold 2277.
Four exons have been identified with possible variants
for the amino acid at position 60 (N60S or N60D). The
initiating methionine is also absent from the genome
sequence of FhCaM2, likely due to an artefact of gen-
ome assembly as this sequence has been characterised
and the initiating methionine confirmed to be present
experimentally [19]. FhCaM3 is also represented by a
single copy on scaffold 1560 where the full gene presents
as three exons with an apparent duplication of exon 3
(amino acids 71–131) within the scaffold. This duplica-
tion likely represents a sequence assembly artefact, as
the surrounding non-CaM coding sequence is identical.
These data show that distinct genes code for the CaM
proteins. Due to the current annotation status of the
genome, we have no data on the relative chromosomal
positions of these genes. Schistosoma mansoni has also
been shown to possess two distinct CaM genes, although
they exhibit high (>99 %) sequence identity relative to
each other [13].
FhCaMs are abundantly expressed in parenchymal cells of
juvenile liver fluke
Juvenile liver fluke were maintained in vitro under two
conditions: (i) RPMI media where the worms survive in
a steady state with no growth or development, and (ii)
RPMI supplemented with bovine serum which allows
the worms to grow in size, with visible development of
the gut [36]. CaM transcript abundance was assessed in
worms maintained for 1-, 3-, 5- and 7-days and com-
pared to respective transcript levels at day 0. FhCaM1,
FhCaM2 and FhCaM3 were expressed in the juvenile
worms and displayed a significant decrease in transcript
abundance (>50 % reduction) compared to those ob-
served at day 0, irrespective of maintenance conditions
within the time assayed (Fig. 1). This may occur because
upon excysting from a quiescent intermediate stage, ju-
venile worms may produce significant amounts of gene
transcripts in preparation for the migratory stage of the
life-cycle. The trends from day 1 onwards show a further
significant diminution of FhCaM1 and FhCaM2, with
FhCaM3 remaining relatively stable. Down regulation of
FhCaM1 and 2 reflects a common transcriptional pat-
tern, where a large proportion of genes are downregu-
lated relative to that occurring in metacercariae, through
NEJ development towards adulthood [23]. Each of the
three CaMs possess distinct ion binding properties and
they have been suggested to play different roles. Western
blot analyses did reveal that FhCaM2 and FhCaM3 are
constitutively expressed until day 21 (data not shown)
suggesting they are both functional within the juvenile
stage of the worms.
Employing polyclonal antisera previously used in adult
worms to localise FhCaM2 to tegumental spines and
FhCaM3 to vitelline cells and eggs [20], we demon-
strated that FhCaM2 and FhCaM3 are expressed much
more widely than previously reported, occurring ubiqui-
tously throughout the parenchymal tissue of juvenile
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fluke (Fig. 2). Using optical sectioning of stained whole-
mount juveniles via confocal microscopy, FhCaM2 and
FhCaM3 immunoreactivities (IRs) were detected
throughout the parenchyma (i.e. sub-tegumental, non-
gut associated tissue) of F. hepatica juveniles (n = 30 in-
dividual worms observed, Fig. 2). FhCaM1-IR was not
detected in any of our samples (n = 30). Note that the
CaM1 antiserum described in the methods did not give
any positive IR in juvenile fluke despite multiple experi-
ments, consistent with the results obtained from adult
flukes [20]. This would indicate that the HsCaM
antiserum could not bind/detect native FhCaM1 despite
high levels of sequence conservation (98.6 %). Although
Fig. 2 presents only FhCaM3 IR, both FhCaM2 and
FhCaM3 antisera displayed identical and similarly diffuse
staining patterns. Aided by the counter-staining of fila-
mentous actin using labelled phalloidin, the immunopo-
sitive cells were found to be localised below the
contractile muscle layers of the body wall (Fig. 2a–d)
representing localisation to both cell bodies and cellular
processes within the parenchyma which lies below the
outer muscular layers and is packed between cells of the
gut and other internal organ systems [37]. IR was evi-
dent within the cytoplasm of distinct cells, with nuclei
remaining unstained (Fig. 2f ). Distinct cytoplasmic pro-
cesses from stained cells were seen extending towards
muscle fibres/the muscle layer (Fig. 2c). Cells within the
parenchyma include tegumental cell bodies [38] and
myocytons (cell bodies) of muscle cells. Myocytons are
the non-contractile portion of muscle cells that are lo-
cated distally to the contractile myofibril [39]. The wide-
spread nature of the localisation shown in Fig. 2 likely
reflects the constitutive roles played by CaMs in fluke
biology. The essentially identical localisation patterns of
FhCaM2 and FhCaM3 make it impossible to suggest
functional differences based solely on the microscopy
data shown here, although it should be noted that
FhCaM2 and FhCaM3 antisera have been tested for spe-
cificity in both western blot and ELISA experiments, and
show no measurable cross-reactivity [20]. Controls omit-
ting primary anti-CaM sera did not display parenchymal
IR, but did exhibit non-specific staining of the outer sur-
face/tegument (data not shown). Therefore, we consider
the surface staining visible in Fig. 2 to be non-specific.
FhCaM RNAi triggers specific suppression of target
transcript and protein
To assess CaM functions in juvenile liver fluke we
employed RNAi methods developed in our laboratory
[21, 22], based on soaking NEJs in ds/siRNA, followed
by maintenance in serum-supplemented RPMI media.
We found that exposure to both dsRNA and siRNAs
triggered appreciable silencing of FhCaM transcripts, as
measured by qPCR. Note that the following data are
expressed as the percentage of transcript remaining
following RNAi treatment, i.e. where 100 % = no change.
Statistical significances are indicated relative to the time/
concentration matched negative control treatment. In
order to silence the three fluke CaM genes, we began by
testing 27 nt siRNAs and long (~200 nt) dsRNAs against
each individual target, as well as the three CaM long
dsRNAs combined into a cocktail. To assess the relative
efficacies of these treatments, each was tested for im-
pacts on CaM transcript knockdown over a 72 h time-
course (i.e. 4 h dsRNA exposure, followed by 68 h
Fig. 1 Expression of FhCaM1 (a), FhCaM2 (b) and FhCaM3 (c) during
maintenance of juvenile Fasciola hepatica +/− serum for 7 days in
vitro. CaM transcript abundance was assessed by qPCR at 1, 3, 5, and
7 days and normalised against the abundance of respective
transcripts in 0 day juvenile fluke. Data represent mean ± SEM of
percentage changes in target transcript abundance relative to a
GAPDH reference transcript. Each bar represents data from at least
five treatment replicates, 20 worms per replicate. Statistical analyses
were performed using One Way ANOVA with Tukey’s post hoc test.
*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001
McCammick et al. Parasites & Vectors  (2016) 9:46 Page 6 of 13
maintenance). These initial experiments, showed that
target transcript knockdown (in all cases relative to
untreated controls) could be triggered by exposure to
individual CaM dsRNAs giving significantly reduced
levels of expression (dsFhCaM1 vs FhCaM1 = 32.3 ±
2.6 %, n = 3, P < 0.01; dsFhCaM2 vs FhCaM2 = 5.9 ±
3.0 %, n = 3, P < 0.01; dsFhCaM3 vs FhCaM3 = 2.5 ±
0.07 %, n = 3, P < 0.001; Fig. 3a–c) as well as by exposure
to a cocktail of all three CaM dsRNAs in combination
(dsRNA cocktail = 100 ng/μl final concentration, i.e. each
individual dsRNA at 33.3 ng/μl) (dsFhCaM1-3 vs
FhCaM1 = 38.3 ± 2.6 %, n = 6, P < 0.01; dsFhCaM1-3 vs
FhCaM2 = 5.6 ± 0.2 %, n = 3, P < 0.01; dsFhCaM1-3 vs
FhCaM3 = 6.9 ± 1.2 %, n = 3, P < 0.001; Fig. 3a–c). Fig. 3
shows that, in all cases, combinatorial long dsRNA
treatments were not significantly different to those of
individual dsRNAs i.e. are equally effective. We also
tested 27 nt siRNAs against each of the three FhCaMs
and found they each induced silencing with significantly
reduced levels of expression (siFhCaM1 vs FhCaM1 =
44.5 ± 6.0 %, n = 6, P < 0.01; siFhCaM2 vs FhCaM2 =
20.7 ± 4.0 %, n = 6, P < 0.001; siFhCaM3 vs FhCaM3 =
25.3 ± 4.2 %, n = 5, P < 0.01; Fig. 3a–c). For all three tar-
gets the siRNAs appeared less effective than the long
dsRNAs; in the cases of FhCaM2 and FhCaM3 these
differences were statistically significant (Student’s t-test:
dsFhCaM2 vs siFhCaM2, P < 0.05; dsFhCaM3 vs siFh-
CaM3, P < 0.01; Fig. 3). Based on these data, we
employed dsRNA cocktails representing FhCaM1-3 in
the rest of the experiments reported here. Elsewhere, si-
lencing induced by long dsRNA and siRNA triggers have
also been reported to produce robust knockdown for up
Fig. 2 Immunocytochemical localisation of calmodulin 3 (FhCaM3) in juvenile Fasciola hepatica. Green immunoreactivity (IR) represents FhCaM3
labelled with fluorescein isothiocyanate, red represents filamentous actin labelled with phalloidin-tetramethylrhodamine isothiocyanate. Images a–d
represent consecutive optical sections taken in the Z-axis (at 1.5 μm intervals), demonstrating the presence of abundant FhCaM3 immunoreactivity (IR)
throughout the sub-tegumental, sub-muscular parenchyma. The bifurcated gut (g) can be seen in b–d. e–f show higher magnification images in
which FhCaM3 IR is visible within cell bodies (cb) and cellular processes (p), while nuclei (n) remain un-stained. Identical staining patterns were ob-
served for FhCaM2 (not shown). These patterns were visualised in 30 samples
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to 7 days with recovery of transcript levels only occur-
ring in siRNA treatment groups by day 14 [40].
We next analysed the longevity of CaM transcript
knockdown in vitro over a 3-week period in order to
begin to assess the time frame over which functional
assays could be run. CaM knockdown persisted at sig-
nificant levels during maintenance (measurements taken
at 7, 14 and 21 days post dsRNA exposure; Fig. 3d–f ),
with transcript levels at day 21 remaining significantly
lower than controls (FhCaM1 = 43.1 ± 4.1 %, n = 4, P <
0.01; FhCaM2 = 1.5 ± 1.5 %, n = 5, P < 0.001; FhCaM3 =
4.0 ± 1.3 %, n = 5, P < 0.001; Fig. 3f ). These data showed
that CaM transcript knockdown persists throughout this
maintenance period; this persistence occurs even in the
absence of dsRNA during maintenance, since worms
were only exposed to dsRNA during the initial 4 h ex-
posure soak. Such long-term maintenance of knockdown
is consistent with our previous observations on RNAi of
liver fluke cathepsin B, L and glutathione transferase
genes, in which we reported the persistence of
Fig. 3 RNA interference (RNAi) of calmodulin (FhCaM) transcripts in juvenile Fasciola hepatica, as measured by relative quantitative PCR (qPCR).
Juvenile fluke exposed to 50 ng/μl short interfering (si)RNA (27 nt) or 100 ng/μl long (~200 nt) double stranded (ds)RNA for 4 h were maintained
for a further 68 h (a–c) or 7 (d), 14 (e) or 21 days (f) before analysis of transcript abundance by qPCR. Over a 72 h time course, impacts of
individual CaM dsRNA, a cocktail of FhCaM1-3 dsRNAs, and siRNAs were tested for impact on abundance of FhCaM1 (a), FhCaM2 (b) and FhCaM3
(c) transcripts, alongside negative control treatments (dsCTRL and siCTRL). Effective combinatorial dsRNA treatments were then tested over longer
timeframes (d–f). Data represent mean ± SEM of percentage changes in target transcript abundance relative to a GAPDH reference transcript,
normalised against the abundance of those transcripts in an untreated control group [27]. Each bar represents data from at least three RNAi
treatment replicates, 20 worms per replicate. Statistical analyses were performed using One Way ANOVA with Dunnett’s post hoc test, or
Student’s t-test (siRNA vs dsRNA comparisons in b, c). *, P < 0.05; **, P < 0.01; ***, P < 0.001
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knockdown for 21 days following a similar RNAi proto-
col [21]. Similarly, electro-soaking methods have also
shown the persistence of silencing effects up to 21 days
[40] and reports from schistosomes illustrate that
electroporation-induced RNAi can be maintained for up
to 40 days [41]. Such persistent silencing in trematodes,
even in the absence of prolonged dsRNA supplementa-
tion, indicates the presence of an efficient dsRNA uptake
and amplification mechanism and bodes well for the
success of putative in vivo RNAi experiments.
Persistent transcript knockdown over a 3-week meas-
urement period suggested that CaM protein suppression
would be detectable during this period, following run-
down of target proteins in line with their cellular half-
lives. As a guide to the time-point at which functional
assays could most effectively be targeted, we performed
western blot-based detection of FhCaM2 and FhCaM3
at 7 and 14 days following dsRNA exposure (Fig. 4).
Using FhCaM2 and FhCaM3 antisera at days 7 and 14
post dsRNA exposure, these proteins exhibit RNAi-
induced suppression relative to time-matched dsCTRL
and untreated controls from day 7 onwards (FhCaM2:
day 7, 37.9 ± 6.3 %, n = 3, P < 0.05; day 14, 27.1 ± 13.3 %,
n = 3, P < 0.01; FhCaM3: day 7, 55.6 ± 5.0, n = 3, P < 0.05;
day 14, 66.2 ± 9.9, n = 3, P < 0.01; Fig. 4). The exception
here was FhCaM3 at day 14, which did not show a sig-
nificant effect compared to untreated control, indicating
either recovery from suppression (although FhCaM3
transcripts remained suppressed beyond this time point),
or a technical issue with our measurement method lead-
ing to a false negative reading in this case. These data
demonstrate that both FhCaM2 and 3 levels were signifi-
cantly lower in dsFhCaM1-3 treatments than in either
control group at day 7; this difference persists until at
least day 14. We therefore proceeded with functional
analyses of the biological consequences of CaM RNAi, at
time points ≥ 7 days post dsRNA exposure.
FhCaM RNAi induces motility and growth phenotypes in
vitro
Assay selection was guided by our hypotheses that CaMs
are involved in worm growth and motility. Previous
work has linked CaM function with growth and develop-
ment of helminths, including reduced growth associated
with CaM silencing in both S. mansoni sporocysts [13],
and in the free-living nematode C. elegans [33]. Recently,
the silencing of adult S. mansoni CaM has implicated
the protein in muscular function and resulted in a
Fig. 4 RNA interference (RNAi)-induced suppression of Fasciola hepatica calmodulins FhCaM2 and FhCaM3 in juvenile fluke. Western blots were
used to measure suppression of both FhCaM2 and 3 relative to a loading control (anti-actin) at both 7 (a) and 14 (b) days following exposure to
CaM double stranded (ds)RNA. All three FhCaM targets were measured in untreated controls, negative control dsRNA treatments (dsCTRL) and a
dsRNA cocktail targeting all three fluke CaMs (dsFhCaM1-3). Reduced band density, indicating suppression of target protein, is apparent in
FhCaM2- and FhCaM3-probed dsFhCaM1-3 treatments at both 7 and 14 days post dsRNA, as evidenced by densitometric analyses of FhCaM2 (c)
and FhCaM3 (d). Each lane represents a single replicate sample, consisting of protein extracted from 50 NEJs per replicate. *, P < 0.05; **, P < 0.01
McCammick et al. Parasites & Vectors  (2016) 9:46 Page 9 of 13
characteristic somatic contraction/dilation phenotype
[14]. Given the persistence of CaM transcript knock-
down (Fig. 3) and significant protein suppression from
day 7 onwards (Fig. 4), we hypothesised that any associ-
ated phenotypes resulting from this suppression would
be similarly detectable from day 7 onwards.
In order to measure impacts of CaM silencing on liver
fluke growth, we employed an assay based on the growth
of juvenile fluke, which can be triggered by the presence
of bovine serum [36]. By digitally measuring the size
(area occupied) of individual worms maintained in FBS-
supplemented RPMI, we found that silencing FhCaMs,
either alone or in combination, inhibited serum-
stimulated growth relative to controls (Fig. 5). Worms
that were maintained for 7 days post dsRNA in vitro,
demonstrated that FhCaM RNAi juveniles grow more
slowly than control treated juveniles (mean ± SEM worm
area in each treatment: untreated, 26,952 ± 452 μm2, n =
124; dsCTRL, 24,820 ± 466 μm2, n = 122; dsFhCaM1,
20,714 ± 784 μm2, n = 42; dsFhCaM2, 18,714 ± 692 μm2,
n = 49; dsFhCaM3, 20,150 ± 710 μm2, n = 40;
dsFhCaM1-3, 21,966 ± 563 μm2, n = 88; Fig. 5). All four
CaM RNAi treatments were statistically significant vs
dsCTRL (P < 0.001). The supplementation of mainten-
ance media with bovine serum was critical in revealing
the growth phenotype associated with CaM disruption
and emphasises the importance of optimising mainten-
ance conditions for future F. hepatica experimentation.
This is the first report of a growth phenotype revealed
by RNAi in any flatworm parasite.
The rationale for investigating the impact of FhCaM
RNAi on fluke motility stemmed partly from our local-
isation data (see Fig. 2), where we suspected that some
of the stained cells in the parenchyma would include
muscle myocytons, combined with the well-documented
role of CaM in regulating smooth muscle contraction
[42]. If that was the case, we hypothesised that FhCaM
RNAi should affect the ability of worms to move and/or
migrate (although CaM suppression may also have been
expected to affect motility via disruption of Ca2
Fig. 5 Calmodulin (CaM) RNA interference (RNAi) triggers aberrant growth and motility phenotypes in juvenile Fasciola hepatica, which are
recapitulated by a CaM antagonising drug. a Fluke assayed for serum-stimulated growth (in RPMI + 20 % foetal bovine serum, FBS) at 7 days post
double stranded (ds)RNA exposure show inhibited growth in individual and combinatorial FhCaM dsRNA treatments vs controls; (b) this phenotype is
recapitulated, over the same time period, by incubation in 0.5 μM or 1 μM trifluoperazine (TFP), an antagonist of CaM; (c) combinatorially-treated
dsFhCaM1-3 fluke show increased migration through an agar-based dispersal assay vs controls at 10 days post dsRNA exposure; (d) increased migration
following CaM inhibition is also seen where worms are treated with TFP. In a and b, data points represent area measurements from individual worms.
In c and d, each data point represents an individual assay plate, where 10 worms were measured per plate. Horizontal lines represent dataset means. *,
P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001
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+-induced synaptic vesicle release, or through more gen-
eral induction of cellular stress associated with wide-
spread Ca2+ disruption). Certainly, data from other
systems link disruption of CaM function with hindered
movement/motility, particularly in ciliated or flagellated
organisms/cells [43]. Impacts of FhCaM RNAi on fluke
motility were quantified based on the ability of worms to
migrate through an agar substrate, across a 5 mm radius
from the point of origin. Performed at 10 days post
dsRNA, this assay illustrated that combinatorially-
treated dsFhCaM1-3 (P < 0.01), but not individual
dsFhCaM treatments, migrated significantly faster than
untreated controls through this assay (proportion of
worms escaping 5 mm radius: untreated, 38.6 ± 5.2 %, n
= 13; dsCTRL, 45.2 ± 5.3 %, n = 13; dsFhCaM1, 33.6 ±
7.1 %, n = 7; dsFhCaM2, 35.3 ± 5.1 %, n = 13; dsFhCaM3,
50.2 ± 6.1 %, n = 13; dsFhCaM1-3, 64.3 ± 5.9 %, n = 12,
P < 0.01; Fig. 5), i.e. worms exposed to a cocktail of three
FhCaM dsRNAs (dsFhCaM1-3) were hyperactive and
migrated more quickly over a 3 h period than untreated
controls. None of the individual dsFhCaM treatments
induced motor phenotypes that were significantly differ-
ent from controls, suggesting that this phenotype may
be the result of removing functional redundancy that
may exist between the three fluke CaM genes.
FhCaM RNAi phenotypes are recapitulated by the CaM
antagonist, trifluoperazine
In order to further validate our RNAi-induced growth
and motility phenotypes, we incubated juvenile worms
in the presence of TFP, a compound with CaM antago-
nising activity. This compound (and another calmodulin
antagonist, W7) has been shown to bind to FhCaM1 and
FhCaM3 [20]. Additionally, CaM antagonists have been
shown to partially block transformation in S. mansoni
miracidia [13] and inhibit hatching of schistosome eggs
[15]. Growth inhibition associated with F. hepatica
CaM-RNAi was also seen in worms maintained in the
presence of the CaM antagonist, TFP, consistent with
the effects of this drug as reported in schistosome sporo-
cysts [13]. Juvenile fluke were assayed after 7 days in the
presence of TFP, with those treated with 0.5 and 1 μM
showing significant reductions in size (P < 0.0001) com-
pared to vehicle controls (untreated (no drug), 28,702 ±
890 μm2, n = 38; vehicle (DMSO) control, 26,775 ±
580 μm2, n = 50; 0.5 μM TFP, 20,276 ± 801 μm2, n = 50;
1 μM TFP, 18,776 ± 737 μm2, n = 60; Fig. 5).
TFP also increased the migratory capacity of juvenile
fluke, in a manner similar to that displayed by FhCaM1-
3 RNAi juveniles. Following an 18 h exposure to concen-
trations of up to 5 μM TFP, we observed an increased
proportion of worms displaying full motility during a
30 s observation in drug, compared to controls (visual
analysis: vehicle (DMSO) control: 6.6 ± 2.8 % moving, n
= 50; 5 μM TFP: 65.5 ± 5.9 % moving, n = 30, P < 0.001;
Fig. 6). This effect was also evident in our agar assay, al-
though only at 10 μM was the effect statistically signifi-
cant vs controls (vehicle (DMSO) control, 13.9 ± 7.0 %,
n = 8; 10 μM TFP, 41.1 ± 8.7 %, n = 10, P < 0.05; Fig. 5).
W-7 hydrochloride also increased the proportion of
worms moving under visual analysis (vehicle (DMSO)
control: 6.6 ± 2.8 % moving, n = 50; 5 μM W-7: 36.8 ±
4.1 % moving, n = 30, P < 0.001; Fig. 6), but this
difference did not translate into a statistically significant
impact on fluke migration in the agar assay (data not
shown).
As with the inhibited growth phenotype discussed
above, this accelerated motility phenotype was recapitu-
lated in the presence of the CaM-inhibiting drug, TFP.
CaM RNAi has not, to our knowledge, been linked to in-
creased motility in any other system to date, although
Fig. 6 CaM antagonists stimulate motility in juvenile Fasciola
hepatica. Increased motility (numbers moving) following CaM
inhibition is seen when worms are treated with TFP (a) and W7 (b)
over a period of 18 h. Each bar represents data from at least three
RNAi treatment replicates, 20 worms per replicate. Statistical analyses
were performed using One Way ANOVA with Dunnett’s post hoc
test. *, P < 0.05; **, P < 0.01; ***, P < 0.001
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TFP has been reported to increase spontaneous muscle
contractions in the filarial nematode Acanthocheilonema
vitae [44]. This increased motility phenotype might
occur due to the disruption of intracellular Ca2+ dynam-
ics in neuromuscular cells, either in muscle cells, by
triggering aberrant contractility, or in neurones, by
impacting on Ca2+-evoked synaptic release. We do not
yet know how increased motility would impact on worm
infectivity under in vivo conditions, although these
experiments are currently in progress. While increased
motility may not make an obvious therapeutic strategy,
it is possible that the increased motility triggered by
CaM RNAi might impact worm survival through in-
creased energy expenditure. Alternatively, stunted
growth and development as observed when FhCaM
function was disrupted by both molecular genetic and
pharmacological means, does represent a desirable
therapeutic outcome. This might reflect either: (i)
FhCaM’s direct involvement in controlling Ca2+ dynam-
ics in dividing cells (Ca2+ fluxes have a well-established
role in the cell cycle; see [45, 46]) where disrupting CaM
function could directly inhibit cell division; or (ii)
FhCaMs are important housekeeping proteins required
for normal cellular function [47], such that FhCaM’s im-
pact on growth occurs via a more general impact on cel-
lular health/function in FhCaM-expressing cells.
Although the data presented in this study cannot further
delineate between these possibilities, growth suppression
could represent an appealing therapeutic outcome fol-
lowing FhCaM-selective drug intervention.
Conclusions
This work represents only the second published study to
use gene-silencing methods to identify aberrant pheno-
types that inform gene function in liver fluke parasites.
We have demonstrated that CaMs are expressed widely
in the parenchyma of the invasive juvenile life stage of F.
hepatica. The development and application of novel F.
hepatica assays demonstrated that CaMs are important
for the normal growth and motility of NEJs. Addition-
ally, the growth phenotype observed was only evident
upon the addition of serum-stimulated development and
we recommend the addition of serum to any further
RNAi experiments in F. hepatica. It is worth noting that
juvenile fluke growth in vitro is slower than that seen in
vivo such that the growth phenotype associated with
FhCaM dysregulation could be markedly enhanced in
vivo. While the increased motility effect does not
implicate FhCaM as an obvious therapeutic target, the
growth defects observed encourage further investigation.
Future work will focus on deciphering functional differ-
ences in the roles of FhCaM1, FhCaM2 and FhCaM3,
particularly during development in vivo. The role of
FhCaMs in growth supports their consideration as con-
trol targets in liver fluke parasites.
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